;PMID: 1846317
;source_file_1934.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..111] = [t:41..111]
;2)section:[e:115..140] = [t:115..140]
;3)section:[e:144..272] = [t:144..272]
;4)sentence:[e:276..352] = [t:276..352]
;5)sentence:[e:354..689] = [t:354..689]
;6)sentence:[e:690..787] = [t:690..787]
;7)sentence:[e:788..1175] = [t:788..1175]
;8)sentence:[e:1176..1319] = [t:1176..1319]
;9)sentence:[e:1320..1418] = [t:1320..1418]
;10)sentence:[e:1419..1690] = [t:1419..1690]
;11)section:[e:1694..1738] = [t:1694..1738]

;section 0 Span:0..35
;Cancer Res. 1991 Feb 1;51(3):794-8.
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..10] Res) (.:[10..11] .) (CD:[12..16] 1991)
        (NNP:[17..20] Feb) (CD:[21..24] 1;5) (CD:[24..25] 1) (NN:[25..26] -LRB-)
        (CD:[26..27] 3) (-RRB-:[27..28] -RRB-) (::[28..29] :) (CD:[29..32] 794)
        (::[32..33] -) (CD:[33..35] 8.)))

;sentence 1 Span:41..111
;Production of large amounts of hydrogen peroxide by human tumor cells.
;[72..89]:substance:"hydrogen peroxide"
(SENT
  (NP-HLN
    (NP (NN:[41..51] Production))
    (PP (IN:[52..54] of)
      (NP
        (NP (JJ:[55..60] large) (NNS:[61..68] amounts))
        (PP (IN:[69..71] of)
          (NP (NN:[72..80] hydrogen) (NN:[81..89] peroxide)))))
    (PP (IN:[90..92] by)
      (NP (JJ:[93..98] human) (NN:[99..104] tumor) (NNS:[105..110] cells)))
    (.:[110..111] .)))

;section 2 Span:115..140
;Szatrowski TP, Nathan CF.
(SEC
  (FRAG (NNP:[115..125] Szatrowski) (NN:[126..128] TP) (,:[128..129] ,)
        (NNP:[130..136] Nathan) (NNP:[137..140] CF.)))

;section 3 Span:144..272
;Beatrice and Samuel A. Seaver Laboratory, Department of Medicine, Cornell 
;University Medical College, New York, New York 10021.
(SEC
  (FRAG (NNP:[144..152] Beatrice) (CC:[153..156] and) (NNP:[157..163] Samuel)
        (NNP:[164..165] A) (.:[165..166] .) (NNP:[167..173] Seaver)
        (NNP:[174..184] Laboratory) (,:[184..185] ,) (NNP:[186..196] Department)
        (IN:[197..199] of) (NNP:[200..208] Medicine) (,:[208..209] ,)
        (NNP:[210..217] Cornell) (NNP:[219..229] University)
        (NNP:[230..237] Medical) (NNP:[238..245] College) (,:[245..246] ,)
        (NNP:[247..250] New) (NNP:[251..255] York) (,:[255..256] ,)
        (NNP:[257..260] New) (NNP:[261..265] York) (.:[266..271] 10021)
        (.:[271..272] .)))

;sentence 4 Span:276..352
;Few nonphagocytic cells are known to generate reactive oxygen intermediates.
;[331..351]:substance:"oxygen intermediates"
(SENT
  (S
    (NP-SBJ-1 (JJ:[276..279] Few) (JJ:[280..293] nonphagocytic)
              (NNS:[294..299] cells))
    (VP (VBP:[300..303] are)
      (VP (VBN:[304..309] known)
        (S
          (NP-SBJ-1 (-NONE-:[309..309] *))
          (VP (TO:[310..312] to)
            (VP (VB:[313..321] generate)
              (NP (JJ:[322..330] reactive)
                 (NN:[331..337] oxygen) (NNS:[338..351] intermediates)))))))
    (.:[351..352] .)))

;sentence 5 Span:354..689
;Based on horseradish peroxidase-dependent, catalase-inhibitable oxidation of 
;fluorescent scopoletin, seven human tumor cell lines constitutively
;elaborated  H2O2 at rates (up to 0.5 nmol/10(4) cells/h) large enough that
;cumulative  amounts at 4 h were comparable to the amount of H2O2 produced by
;phorbol  ester-triggered neutrophils.
;[363..385]:substance:"horseradish peroxidase"
;[397..405]:substance:"catalase"
;[444..454]:substance:"scopoletin"
;[512..516]:substance:"H2O2"
;[533..536]:quantitative-value:"0.5"
;[537..555]:quantitative-units:"nmol/10(4) cells/h"
;[598..599]:quantitative-value:"4"
;[600..601]:quantitative-units:"h"
;[635..639]:substance:"H2O2"
;[652..666]:substance:"phorbol  ester"
(SENT
  (S
    (S-ADV
      (NP-SBJ-1 (-NONE-:[354..354] *))
      (VP (VBN:[354..359] Based)
        (NP-1 (-NONE-:[359..359] *))
        (PP-CLR (IN:[360..362] on)
          (NP
            (NP
              (ADJP
                (NML (NN:[363..374] horseradish) (NN:[375..385] peroxidase))
                (HYPH:[385..386] -) (JJ:[386..395] dependent))
              (,:[395..396] ,)
              (ADJP (NN:[397..405] catalase) (HYPH:[405..406] -)
                    (JJ:[406..417] inhibitable))
              (NN:[418..427] oxidation))
            (PP (IN:[428..430] of)
              (NP (JJ:[432..443] fluorescent) (NN:[444..454] scopoletin)))))))
    (,:[454..455] ,)
    (NP-SBJ (CD:[456..461] seven) (JJ:[462..467] human) (NN:[468..473] tumor)
            (NN:[474..478] cell) (NNS:[479..484] lines))
    (ADVP (RB:[485..499] constitutively))
    (VP (VBD:[500..510] elaborated)
      (NP (NN:[512..516] H2O2))
      (PP (IN:[517..519] at)
        (NP
          (NP (NNS:[520..525] rates)
            (PRN (-LRB-:[526..527] -LRB-)
              (NP
                (NP
                  (QP (RB:[527..529] up) (TO:[530..532] to) (CD:[533..536] 0.5))
                  (NN:[537..541] nmol))
                (PP (SYM:[541..542] /)
                  (NP (CD:[542..547] 10-LRB-4-RRB-) (NNS:[548..553] cells)))
                (PP (SYM:[553..554] /)
                  (NP (NN:[554..555] h))))
              (-RRB-:[555..556] -RRB-)))
          (ADJP
            (ADJP (JJ:[557..562] large) (RB:[563..569] enough))
            (SBAR (IN:[570..574] that)
              (S
                (NP-SBJ
                  (NP (JJ:[575..585] cumulative) (NNS:[587..594] amounts))
                  (PP-TMP (IN:[595..597] at)
                    (NP (CD:[598..599] 4) (NN:[600..601] h))))
                (VP (VBD:[602..606] were)
                  (ADJP-PRD (JJ:[607..617] comparable)
                    (PP (TO:[618..620] to)
                      (NP
                        (NP (DT:[621..624] the) (NN:[625..631] amount))
                        (PP (IN:[632..634] of)
                          (NP
                            (NP (NN:[635..639] H2O2))
                            (VP (VBN:[640..648] produced)
                              (NP (-NONE-:[648..648] *))
                              (PP (IN:[649..651] by)
                                (NP
                                  (ADJP
                                    (NML (NN:[652..659] phorbol)
                                         (NN:[661..666] ester))
                                    (HYPH:[666..667] -)
                                     (VBN:[667..676] triggered))
                                  (NNS:[677..688] neutrophils))))))))))))))))
    (.:[688..689] .)))

;sentence 6 Span:690..787
;Superoxide dismutase-inhibitable ferricytochrome c  reduction was detectable
;at much lower rates.
;[690..710]:substance:"Superoxide dismutase"
;[723..740]:substance:"ferricytochrome c"
(SENT
  (S
    (NP-SBJ
      (ADJP
        (NML (NN:[690..700] Superoxide) (NN:[701..710] dismutase))
        (HYPH:[710..711] -) (JJ:[711..722] inhibitable))
      (NML (NN:[723..738] ferricytochrome) (NN:[739..740] c))
      (NN:[742..751] reduction))
    (VP (VBD:[752..755] was)
      (ADJP-PRD (JJ:[756..766] detectable))
      (PP (IN:[767..769] at)
        (NP
          (ADJP (RB:[770..774] much) (JJR:[775..780] lower))
          (NNS:[781..786] rates))))
    (.:[786..787] .)))

;sentence 7 Span:788..1175
;H2O2 production was inhibited by  diphenyleneiodonium, a flavoprotein binder
;(concentration producing 50%  inhibition, 0.3 microM), and
;diethyldithiocarbamate, a divalent cation chelator  (concentration producing
;50% inhibition, 3 microM), but not by cyanide or azide,  inhibitors of
;electron transport, or by agents that inhibit xanthine oxidase,  polyamine
;oxidase, or cytochrome P450.
;[788..792]:substance:"H2O2"
;[822..841]:substance:"diphenyleneiodonium"
;[845..857]:substance:"flavoprotein"
;[858..864]:substance:"binder"
;[890..893]:quantitative-value:"50%"
;[907..910]:quantitative-value:"0.3"
;[911..917]:quantitative-units:"microM"
;[924..946]:substance:"diethyldithiocarbamate"
;[959..974]:substance:"cation chelator"
;[1001..1004]:quantitative-value:"50%"
;[1017..1018]:quantitative-value:"3"
;[1019..1025]:quantitative-units:"microM"
;[1039..1046]:substance:"cyanide"
;[1050..1055]:substance:"azide"
;[1098..1104]:substance:"agents"
;[1118..1134]:substance:"xanthine oxidase"
;[1137..1154]:substance:"polyamine oxidase"
;[1159..1174]:cyp450:"cytochrome P450"
(SENT
  (S
    (NP-SBJ-4 (NN:[788..792] H2O2) (NN:[793..803] production))
    (VP (VBD:[804..807] was)
      (VP
        (VP (VBN:[808..817] inhibited)
          (NP-4 (-NONE-:[817..817] *))
          (PP=3 (IN:[818..820] by)
            (NP-LGS
              (NP
                (NP (NN:[822..841] diphenyleneiodonium))
                (,:[841..842] ,)
                (NP (DT:[843..844] a) (NN:[845..857] flavoprotein)
                    (NN:[858..864] binder))
                (PRN (-LRB-:[865..866] -LRB-)
                  (S
                    (NP-SBJ
                      (NP (NN:[866..879] concentration))
                      (VP (VBG:[880..889] producing)
                        (NP
                          (NML-EXT (CD:[890..892] 50) (NN:[892..893] %))
                          (NN:[895..905] inhibition))))
                    (,:[905..906] ,)
                    (NP-PRD (CD:[907..910] 0.3) (NN:[911..917] microM)))
                  (-RRB-:[917..918] -RRB-)))
              (,:[918..919] ,) (CC:[920..923] and)
              (NP
                (NP (NN:[924..946] diethyldithiocarbamate))
                (,:[946..947] ,)
                (NP (DT:[948..949] a) (JJ:[950..958] divalent)
                   (NN:[959..965] cation) (NN:[966..974] chelator))
                (PRN (-LRB-:[976..977] -LRB-)
                  (S
                    (NP-SBJ
                      (NP (NN:[977..990] concentration))
                      (VP (VBG:[991..1000] producing)
                        (NP
                          (NML-EXT (CD:[1001..1003] 50) (NN:[1003..1004] %))
                          (NN:[1005..1015] inhibition))))
                    (,:[1015..1016] ,)
                    (NP-PRD (CD:[1017..1018] 3) (NN:[1019..1025] microM)))
                  (-RRB-:[1025..1026] -RRB-))))))
        (,:[1026..1027] ,) (CC:[1028..1031] but)
        (VP (RB:[1032..1035] not)
          (PP=3
            (PP (IN:[1036..1038] by)
              (NP-LGS
                (NP (NN:[1039..1046] cyanide) (CC:[1047..1049] or)
                    (NN:[1050..1055] azide))
                (,:[1055..1056] ,)
                (NP
                  (NP (NNS:[1058..1068] inhibitors))
                  (PP (IN:[1069..1071] of)
                    (NP (NN:[1072..1080] electron) (NN:[1081..1090] transport))))))
            (,:[1090..1091] ,) (CC:[1092..1094] or)
            (PP (IN:[1095..1097] by)
              (NP-LGS
                (NP (NNS:[1098..1104] agents))
                (SBAR
                  (WHNP-1 (WDT:[1105..1109] that))
                  (S
                    (NP-SBJ-1 (-NONE-:[1109..1109] *T*))
                    (VP (VBP:[1110..1117] inhibit)
                      (NP
                        (NP (NN:[1118..1126] xanthine) (NN:[1127..1134] oxidase))
                        (,:[1134..1135] ,)
                        (NP (NN:[1137..1146] polyamine)
                            (NN:[1147..1154] oxidase))
                        (,:[1154..1155] ,) (CC:[1156..1158] or)
                        (NP (NN:[1159..1169] cytochrome) (NN:[1170..1174] P450))))))))))))
    (.:[1174..1175] .)))

;sentence 8 Span:1176..1319
;Cytochrome b559, present in human  phagocytes and lymphocytes, was
;undetectable in these tumor cells by a sensitive  spectrophotometric method.
;[1176..1191]:cyp450:"Cytochrome b559"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1176..1186] Cytochrome) (NN:[1187..1191] b559))
      (,:[1191..1192] ,)
      (ADJP (JJ:[1193..1200] present)
        (PP-LOC (IN:[1201..1203] in)
          (NP
            (NP
              (ADJP-1 (JJ:[1204..1209] human))
              (NNS:[1211..1221] phagocytes))
            (CC:[1222..1225] and)
            (NP
              (ADJP-1 (-NONE-:[1225..1225] *P*))
              (NNS:[1226..1237] lymphocytes))))))
    (,:[1237..1238] ,)
    (VP (VBD:[1239..1242] was)
      (ADJP-PRD (JJ:[1243..1255] undetectable)
        (PP-LOC (IN:[1256..1258] in)
          (NP (DT:[1259..1264] these) (NN:[1265..1270] tumor)
              (NNS:[1271..1276] cells)))
        (PP-MNR (IN:[1277..1279] by)
          (NP (DT:[1280..1281] a) (JJ:[1282..1291] sensitive)
              (JJ:[1293..1311] spectrophotometric) (NN:[1312..1318] method)))))
    (.:[1318..1319] .)))

;sentence 9 Span:1320..1418
;Mouse fibroblasts transfected with human tyrosinase  complementary DNA made
;melanin, but not H2O2.
;[1361..1371]:substance:"tyrosinase"
;[1387..1390]:substance:"DNA"
;[1396..1403]:substance:"melanin"
;[1413..1417]:substance:"H2O2"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1320..1325] Mouse) (NNS:[1326..1337] fibroblasts))
      (VP (VBN:[1338..1349] transfected)
        (NP (-NONE-:[1349..1349] *))
        (PP (IN:[1350..1354] with)
          (NP
            (NML (JJ:[1355..1360] human) (NN:[1361..1371] tyrosinase))
            (JJ:[1373..1386] complementary) (NN:[1387..1390] DNA)))))
    (VP
      (VP (VBD:[1391..1395] made)
        (NP=2 (NN:[1396..1403] melanin)))
      (,:[1403..1404] ,) (CC:[1405..1408] but)
      (VP (RB:[1409..1412] not)
        (NP=2 (NN:[1413..1417] H2O2))))
    (.:[1417..1418] .)))

;sentence 10 Span:1419..1690
;Constitutive generation of large  amounts of reactive oxygen intermediates,
;if it occurs in vivo, might contribute  to the ability of some tumors to
;mutate, inhibit antiproteases, injure local  tissues, and therefore promote
;tumor heterogeneity, invasion, and metastasis.
;[1473..1493]:substance:"oxygen intermediates"
;[1584..1597]:substance:"antiproteases"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1419..1431] Constitutive) (NN:[1432..1442] generation))
      (PP (IN:[1443..1445] of)
        (NP
          (NP (JJ:[1446..1451] large) (NNS:[1453..1460] amounts))
          (PP (IN:[1461..1463] of)
            (NP (JJ:[1464..1472] reactive)
               (NN:[1473..1479] oxygen) (NNS:[1480..1493] intermediates))))))
    (,:[1493..1494] ,)
    (SBAR-ADV (IN:[1495..1497] if)
      (S
        (NP-SBJ (PRP:[1498..1500] it))
        (VP (VBZ:[1501..1507] occurs)
          (ADVP (FW:[1508..1510] in) (FW:[1511..1515] vivo)))))
    (,:[1515..1516] ,)
    (VP (MD:[1517..1522] might)
      (VP (VB:[1523..1533] contribute)
        (PP-CLR (TO:[1535..1537] to)
          (NP
            (NP (DT:[1538..1541] the) (NN:[1542..1549] ability)
              (S-2 (-NONE-:[1549..1549] *ICH*)))
            (PP (IN:[1550..1552] of)
              (NP (DT:[1553..1557] some) (NNS:[1558..1564] tumors)))
            (S-2
              (NP-SBJ (-NONE-:[1564..1564] *))
              (VP (TO:[1565..1567] to)
                (VP
                  (VP (VB:[1568..1574] mutate))
                  (,:[1574..1575] ,)
                  (VP (VB:[1576..1583] inhibit)
                    (NP (NNS:[1584..1597] antiproteases)))
                  (,:[1597..1598] ,)
                  (VP (VB:[1599..1605] injure)
                    (NP (JJ:[1606..1611] local) (NNS:[1613..1620] tissues)))
                  (,:[1620..1621] ,) (CC:[1622..1625] and)
                  (VP
                    (ADVP (RB:[1626..1635] therefore))
                    (VB:[1636..1643] promote)
                    (NP
                      (NP
                        (NML-1 (NN:[1644..1649] tumor))
                        (NN:[1650..1663] heterogeneity))
                      (,:[1663..1664] ,)
                      (NP
                        (NML-1 (-NONE-:[1664..1664] *P*))
                        (NN:[1665..1673] invasion))
                      (,:[1673..1674] ,) (CC:[1675..1678] and)
                      (NP
                        (NML-1 (-NONE-:[1678..1678] *P*))
                        (NN:[1679..1689] metastasis)))))))))))
    (.:[1689..1690] .)))

;section 11 Span:1694..1738
;PMID: 1846317 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1694..1698] PMID) (::[1698..1699] :) (CD:[1700..1707] 1846317)
        (NN:[1708..1709] -LSB-) (NNP:[1709..1715] PubMed) (::[1716..1717] -)
        (NN:[1718..1725] indexed) (IN:[1726..1729] for)
        (NNP:[1730..1738] MEDLINE-RSB-)))
